Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v2.4.1.9
Consolidated Balance Sheets (USD $)
Nov. 30, 2014
Nov. 30, 2013
Current Assets    
Cash and cash equivalents $ 3,279,267us-gaap_CashAndCashEquivalentsAtCarryingValue $ 3,925,156us-gaap_CashAndCashEquivalentsAtCarryingValue
Restricted cash 204,141us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue 968,130us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue
Marketable securities 102,674us-gaap_MarketableSecuritiesCurrent 37,910us-gaap_MarketableSecuritiesCurrent
Accounts receivable (net of allowance for doubtful accounts of $1,976,966 and $1,994,575, respectively ) 4,071,997us-gaap_AccountsReceivableNetCurrent 3,336,460us-gaap_AccountsReceivableNetCurrent
Note receivable 0us-gaap_AccountsAndNotesReceivableNet 550,782us-gaap_AccountsAndNotesReceivableNet
Prepaid expenses 710,754us-gaap_PrepaidExpenseCurrent 489,985us-gaap_PrepaidExpenseCurrent
Other current assets 123,126us-gaap_OtherAssetsCurrent 154,984us-gaap_OtherAssetsCurrent
Total current assets 8,491,959us-gaap_AssetsCurrent 9,463,407us-gaap_AssetsCurrent
Property and Equipment-net 953,415us-gaap_PropertyPlantAndEquipmentNet 1,207,279us-gaap_PropertyPlantAndEquipmentNet
Other Assets    
Investment in Saneron CCEL Therapeutics, Inc. 684,000us-gaap_EquityMethodInvestments 684,000us-gaap_EquityMethodInvestments
Deposits and other assets, net 80,212ccel_DepositsAndOtherAssets 146,116ccel_DepositsAndOtherAssets
Total other assets 764,212us-gaap_OtherAssetsNoncurrent 830,116us-gaap_OtherAssetsNoncurrent
Total assets 10,209,586us-gaap_Assets 11,500,802us-gaap_Assets
Current Liabilities    
Accounts payable 992,910us-gaap_AccountsPayableCurrent 1,194,825us-gaap_AccountsPayableCurrent
Accrued expenses 1,471,699us-gaap_AccruedLiabilitiesCurrent 1,800,811us-gaap_AccruedLiabilitiesCurrent
Deferred revenue 6,662,552us-gaap_DeferredRevenueCurrent 6,814,797us-gaap_DeferredRevenueCurrent
Total current liabilities 9,127,161us-gaap_LiabilitiesCurrent 9,810,433us-gaap_LiabilitiesCurrent
Other Liabilities    
Deferred revenue, net of current portion 9,509,088us-gaap_DeferredRevenueNoncurrent 8,658,354us-gaap_DeferredRevenueNoncurrent
Long-term liability - revenue sharing agreements 2,300,000us-gaap_LongTermDebtNoncurrent 2,300,000us-gaap_LongTermDebtNoncurrent
Total other liabilities 11,809,088us-gaap_OtherLiabilitiesNoncurrent 10,958,354us-gaap_OtherLiabilitiesNoncurrent
Commitments and Contingencies (Note 7)      
Stockholders' Deficit    
Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding, and 20,000 authorized and none issued and outstanding of Series A Junior participating preferred stock)      
Common stock ($.01 par value, 20,000,000 authorized; 11,921,285 issued and 9,706,174 outstanding as of November 30, 2014 and 11,870,040 issued and 10,743,225 outstanding as of November 30, 2013) 119,213us-gaap_CommonStockValue 118,700us-gaap_CommonStockValue
Additional paid-in capital 27,842,106us-gaap_AdditionalPaidInCapitalCommonStock 27,265,340us-gaap_AdditionalPaidInCapitalCommonStock
Treasury stock, at cost (5,112,648)us-gaap_TreasuryStockValue (2,926,123)us-gaap_TreasuryStockValue
Accumulated deficit (33,575,334)us-gaap_RetainedEarningsAccumulatedDeficit (33,725,902)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' deficit (10,726,663)us-gaap_StockholdersEquity (9,267,985)us-gaap_StockholdersEquity
Total liabilities and stockholders' deficit $ 10,209,586us-gaap_LiabilitiesAndStockholdersEquity $ 11,500,802us-gaap_LiabilitiesAndStockholdersEquity